Product Description
NX-13 is a first-in-class, orally-active, gut-restricted, small molecule therapeutic candidate for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). NX-13 targets NLRX1, a mitochondria-associated receptor with the ability to modulate immune responses. By activating the NLRX1 pathway, NX-13 increases autophagy and oxidative phosphorylation in immune cells while decreasing differentiation of effector CD4+ T cells, reactive oxygen species, inflammasome formation and production of inflammatory cytokines. (Sourced from: https://ir.landosbiopharma.com/news-releases/news-release-details/landos-biopharma-announces-first-patient-dosed-phase-1b-study-nx)
Mechanisms of Action: NLRX1 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Italy, Poland
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Reported - AbbVie announced they will present P2 Colitis, Ulcerative results in 4Q24 for Amelenodor
- Clinical Outcomes Reported - AbbVie presented P2 Colitis, Ulcerative results on 2024-02-23 for Amelenodor
- Clinical Outcomes Reported - AbbVie presented P1 Colitis|Colitis, Ulcerative results on 2023-11-21 for Amelenodor
Highest Development Phases
Phase 2: Colitis, Ulcerative
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2022-503005-38-00 |
NX-13-201/M25-484 | P2 |
Completed |
Colitis, Ulcerative |
2025-04-08 |
2025-05-02 |
Treatments |